BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. The company is headquartered in Stony Brook, New York and currently employs 26 full-time employees. The company went IPO on 2001-08-24. Its segments include digital asset treasury, therapeutic deoxyribonucleic acid (DNA) production services, DNA tagging and security products and services. Its digital asset treasury segment is engaged in managing digital assets. Its therapeutic DNA production services segment is engaged in nucleic-acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP and LineaIVT. Its DNA tagging and security products and services segment is engaged in the manufacture and detection of DNA for industrial supply chains and security services. Its subsidiary LineaRx, Inc., is engaged in commercializing nucleic acid production solutions for the biopharmaceutical and diagnostics markets.
根據最新的財務報表(Form-10K),BNB Plus Corp 的總資產為 $0,淨損失為 $0
BNBX 的關鍵財務比率是什麼?
BNB Plus Corp 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
BNB Plus Corp 的收入按細分市場或地理位置如何劃分?
BNB Plus Corp 最大收入來源為 Deoxyribonucleic Acid Tagging and Security Products,在最近的收益報告中收入為 1,148,817。就地區而言,Asia and Other 是 BNB Plus Corp 的主要市場,收入為 1,020,556。